Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Fiche publication
Date publication
novembre 2014
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ROLLAND Delphine
Tous les auteurs :
Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Elenitoba-Johnson KS, Betz BL
Lien Pubmed
Résumé
Ameloblastoma is an odontogenic neoplasm whose overall mutational landscape has not been well characterized. We sought to characterize pathogenic mutations in ameloblastoma and their clinical and functional significance with an emphasis on the mitogen-activated protein kinase (MAPK) pathway.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Alleles, Ameloblastoma, genetics, Biomarkers, Tumor, genetics, Cell Line, Tumor, Child, Female, Humans, Jaw Neoplasms, genetics, Middle Aged, Mitogen-Activated Protein Kinases, genetics, Mutation, genetics, Proto-Oncogene Proteins B-raf, genetics, Receptor, Fibroblast Growth Factor, Type 2, genetics, Signal Transduction, genetics, Young Adult, ras Proteins, genetics
Référence
Clin Cancer Res. 2014 Nov 1;20(21):5517-26